Basking is developing the first reversible thrombolytic therapy for acute ischemic stroke (AIS). The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases conducted by company founders Bruce Sullenger and Dr. Shahid Nimjee at Duke University and The Ohio State University Wexner Medical Center. The Company’s candidate drug, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031. DTRI-031 will enter Phase 1 in Q3 of 2021. Basking’s paired therapy has the potential to extend the treatment window, significantly expand the population of patients that receive acute thrombolytic therapy and aligns perfectly with the urgent need in medicine for precision-based therapeutics in cardiovascular disease.
Basking Biosciences is presenting as part of the NIH Innovation Zone.